Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levomepromazine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Neuraxpharm Announces Closing of Acquisition of Established Products from Sanofi
Details : The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal,...
Product Name : Nozinan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 02, 2023
Lead Product(s) : Levomepromazine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Levomepromazine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of se...
Product Name : Nozinan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 07, 2022
Lead Product(s) : Levomepromazine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Neuraxpharm
Deal Size : Undisclosed
Deal Type : Acquisition